Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer

@article{Pourgholami2009PhaseIC,
  title={Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer},
  author={Mohammad Hossein Pourgholami and Michael Szwajcer and Melvin Chin and Winston Spencer Liauw and Jonathan Seef and Samantha J Broyd and David L Morris and Matthew Jon Links},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2009},
  volume={65},
  pages={597-605}
}
Albendazole is a potential anticancer agent that is currently under development for the treatment of cancer. We carried out a dose-finding phase I study of oral albendazole in patients with advanced malignancies. Thirty-six patients with refractory solid tumors were enrolled. Albendazole was given orally on a day 1–14 of a 3 weekly cycle, starting at 400 mg BD with dose escalation until 1,200 mg BD. Serial blood samples were collected up to 96 h and also on day 8 of cycles 1 and 4. The maximum… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Pharmacokinetic optimisation of the treatment of neurocysticercosis.

Clinical pharmacokinetics • 1998
View 2 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…